Skip to main content

Remote Job Finders (RJF)

With oral obesity race underway, all eyes are on Lilly’s Foundayo launch

Novo Nordisk’s oral Wegovy has a few months’ head start on Eli Lilly’s newly approved pill. While the Indianapolis pharma has come from behind the Danish rival in the weight loss space before, last time it clearly had the better drug.

GSK again pulls application for leucovorin, touted by FDA as potential autism treatment

GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to treat cerebral folate deficiency with “autistic features.”
Scroll to top